Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 29, 2009

Solvay to Supply MediGene’s Genital Warts Therapy in Three European Countries

  • Solvay’s German affiliate, Solvay Arzneimittel, negotiated a license and supply agreement with MediGene for the latter’s topical genital warts treatment, Veregen®, in Germany, Austria, and Switzerland. MediGene will provide Solvay with the finished product and could receive milestones and sales-related payments of up to €3.65 million (about $5.31 million) plus royalties on net sales.

    German marketing authorization for Veregen® was granted on September 9 and represents the first for the drug in Europe. MediGene says that Germany will now represent the reference member state for the EU’s decentralized regulatory process and will provide the basis for additional marketing authorization applications to be submitted in other European countries.

    Regulatory submission has also been assessed positively by the Austrian and Spanish national authorities. Formal marketing authorizations in Austria and Spain are expected within the next few months, the company adds.

    Veregen has been available in the U.S. for the treatment of external genital warts since December 2007. It is now marketed in the U.S. by Nycomed, which took over MediGene’s original sales partner Bradley Pharmaceuticals at the end of 2007.

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »